Slawomir Andrzejewski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Slawomir Andrzejewski has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Christopher J. Layton
LVF Ophthalmology Research Centre, Translational Research Institute, Brisbane, Australia
5 shared publications - Jason C. Steel
School of Health, Medical and Applied Sciences, Central Queensland University, Rockhampton, Australia
4 shared publications A. Murali
Faculty of Medicine University of Queensland Brisbane Australia
2 shared publications- Aparna Murali
LVF Ophthalmology Research Centre, Translational Research Institute, Woolloongabba, Queensland, Australia
2 shared publications B. Dhungel
Faculty of Medicine University of Queensland Brisbane Australia
2 shared publications- Bijay Dhungel
Gene & Stem Cell Therapy Program Centenary Institute, The University of Sydney, Camperdown, NSW 2050, Australia
2 shared publications
Latest Publications
- 10 February 2021
- Published by University of Queensland Library
Aspects of posterior segment therapeutic targeting in retinal diseases
- 10 February 2021
- Published by University of Queensland Library
Aspects of posterior segment therapeutic targeting in retinal diseases
- 15 June 2020
- Published by Springer Nature in Gene Therapy
- Vol. 28 (5) , 242-255
Neutralisation of adeno-associated virus transduction by human vitreous humour
Neutralising antibodies (NAbs), caused by past adeno-associated virus (AAV) infection, represent a critical challenge for AAV-mediated gene therapy, with even low NAb titres capable of inhibiting gene transfer, however in protein-rich environments such as the vitreous it is expected that other constituents could also interact with the transduction process. Inhibition of AAV2/2, AAV2/5, AAV2/6 and AAV2/8 transduction by human vitreous humour (VH) obtained from 80 post-mortem eye cups was investigated in this report, with clinically relevant vitreous dilutions as low as 1:2. Unexpectedly, the highest prevalence of inhibition of transduction was observed against AAV2/6, with 66% of tested samples displaying neutralisation at a 1:2 VH dilution. Only two samples showed inhibition of AAV2/8, indicating this serotype is an attractive vector for use in non-vitrectomised eyes of unscreened individuals. Levels of anti-AAV NAbs observed in the VH were much lower than previously observed in serum of a similar Australian population. Among ten tested eye cup pairs, we observed only small variation in anti-AAV NAbs levels between the left and right eye cups. Interaction with 1:2 diluted VH had an augmentation effect on AAV2/8 transduction (p = 0.004), a phenomenon which was not due to albumin or transferrin and which, if developed, might benefit the use of AAV2/8 in clinical settings.
- 15 June 2020
- Published by Springer Nature in Gene Therapy
- Vol. 28 (5) , 242-255
Neutralisation of adeno-associated virus transduction by human vitreous humour
Neutralising antibodies (NAbs), caused by past adeno-associated virus (AAV) infection, represent a critical challenge for AAV-mediated gene therapy, with even low NAb titres capable of inhibiting gene transfer, however in protein-rich environments such as the vitreous it is expected that other constituents could also interact with the transduction process. Inhibition of AAV2/2, AAV2/5, AAV2/6 and AAV2/8 transduction by human vitreous humour (VH) obtained from 80 post-mortem eye cups was investigated in this report, with clinically relevant vitreous dilutions as low as 1:2. Unexpectedly, the highest prevalence of inhibition of transduction was observed against AAV2/6, with 66% of tested samples displaying neutralisation at a 1:2 VH dilution. Only two samples showed inhibition of AAV2/8, indicating this serotype is an attractive vector for use in non-vitrectomised eyes of unscreened individuals. Levels of anti-AAV NAbs observed in the VH were much lower than previously observed in serum of a similar Australian population. Among ten tested eye cup pairs, we observed only small variation in anti-AAV NAbs levels between the left and right eye cups. Interaction with 1:2 diluted VH had an augmentation effect on AAV2/8 transduction (p = 0.004), a phenomenon which was not due to albumin or transferrin and which, if developed, might benefit the use of AAV2/8 in clinical settings.
- 8 April 2019
- Published by Springer Nature in Gene Therapy
- Vol. 26 (6) , 250-263
Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus
Recombinant Adeno-associated viruses (AAVs) are an attractive vector for gene therapy delivery which may be blocked by AAV neutralising antibodies (NAbs). As Type 1 Diabetes (T1DM) is an endocrine disease of immunological origin, it is likely that NAb profiles are altered in the disease. In this study NAb to AAV2, AAV5, AAV6, and AAV8 in 72 subjects with T1DM and 45 non-diabetic patients were measured over a 4-year follow-up period. AAV2 NAb titres were significantly lower in non-diabetic subjects (P = 0.036). The T1DM group had more AAV8 NAb activity at baseline (P = 0.019), whilst after 4 years follow-up the T1DM group displayed developed increased AAV 5 (P = 0.03), 6 (P = 0.03) and 8 (P = 0.002) activity relative to the control group, however, overall AAV5 and 8 NAb levels were very low in patients <40. AAV NAb titre activity and prevalence generally appears higher in T1DM, however, low levels of AAV 5 and 8, particular in younger adult age groups at which T1DM can be targeted, could make these attractive vectors to target the disease.
- 8 April 2019
- Published by Springer Nature in Gene Therapy
- Vol. 26 (6) , 250-263
Adeno-associated virus neutralising antibodies in type 1 diabetes mellitus
Recombinant Adeno-associated viruses (AAVs) are an attractive vector for gene therapy delivery which may be blocked by AAV neutralising antibodies (NAbs). As Type 1 Diabetes (T1DM) is an endocrine disease of immunological origin, it is likely that NAb profiles are altered in the disease. In this study NAb to AAV2, AAV5, AAV6, and AAV8 in 72 subjects with T1DM and 45 non-diabetic patients were measured over a 4-year follow-up period. AAV2 NAb titres were significantly lower in non-diabetic subjects (P = 0.036). The T1DM group had more AAV8 NAb activity at baseline (P = 0.019), whilst after 4 years follow-up the T1DM group displayed developed increased AAV 5 (P = 0.03), 6 (P = 0.03) and 8 (P = 0.002) activity relative to the control group, however, overall AAV5 and 8 NAb levels were very low in patients <40. AAV NAb titre activity and prevalence generally appears higher in T1DM, however, low levels of AAV 5 and 8, particular in younger adult age groups at which T1DM can be targeted, could make these attractive vectors to target the disease.
- 10 December 2018
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 47 (2) , 274-285
Retinal explant culture: A platform to investigate human neuro‐retina
The retina is the tissue responsible for light detection, in which retinal neurons convert light energy into electrical signals to be transported towards the visual cortex. Damage of retinal neurons leads to neuronal cell death and retinal pathologies, compromising visual acuity and eventually leading to irreversible blindness. Models of retinal neurodegeneration include 2D systems like cell lines, disassociated cultures and co‐cultures, and 3D models like organoids, organotypic retinal cultures and animal models. Of these, ex vivo human retinal cultures are arguably the most suitable models for translational research as they retain complex inter‐cellular interactions of the retina and precisely mimic in‐situ responses. In this review, we summarize the distinguishing features of the human retina which are important to preserve in experimental culture, the historical development of human retinal culture systems, the factors affecting ex vivo human retinal culture and the applications and challenges associated with current methods of human retinal explant culture.
- 10 December 2018
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 47 (2) , 274-285
Retinal explant culture: A platform to investigate human neuro‐retina
The retina is the tissue responsible for light detection, in which retinal neurons convert light energy into electrical signals to be transported towards the visual cortex. Damage of retinal neurons leads to neuronal cell death and retinal pathologies, compromising visual acuity and eventually leading to irreversible blindness. Models of retinal neurodegeneration include 2D systems like cell lines, disassociated cultures and co‐cultures, and 3D models like organoids, organotypic retinal cultures and animal models. Of these, ex vivo human retinal cultures are arguably the most suitable models for translational research as they retain complex inter‐cellular interactions of the retina and precisely mimic in‐situ responses. In this review, we summarize the distinguishing features of the human retina which are important to preserve in experimental culture, the historical development of human retinal culture systems, the factors affecting ex vivo human retinal culture and the applications and challenges associated with current methods of human retinal explant culture.
- 21 October 2018
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 47 (4) , 521-536
Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations
Voretigene neparvovec‐rzyl was recently approved for the treatment of Leber congenital amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size and is highly compartmentalized, significantly reducing systemic spread. Adeno‐associated virus (AAV), with its low pathogenicity, prolonged expression profile and ability to transduce multiple cell types, has become the leading gene therapy vector. Target diseases have moved beyond currently untreatable inherited dystrophies to common, partially treatable acquired conditions such as exudative age‐related macular degeneration and glaucoma, but use of the technology in these conditions imposes added obligations for caution in vector design. This review discusses the current status of AAV gene therapy trials in genetic and acquired ocular diseases, and explores new scientific developments, which could help ensure effective and safe use of the therapy in the future.
- 21 October 2018
- Published by Wiley in Clinical & Experimental Ophthalmology
- Vol. 47 (4) , 521-536
Gene therapy and the adeno‐associated virus in the treatment of genetic and acquired ophthalmic diseases in humans: Trials, future directions and safety considerations
Voretigene neparvovec‐rzyl was recently approved for the treatment of Leber congenital amaurosis, and the use of gene therapy for eye disease is attracting even greater interest. The eye has immune privileged status, is easily accessible, requires a reduced dosage of therapy due to its size and is highly compartmentalized, significantly reducing systemic spread. Adeno‐associated virus (AAV), with its low pathogenicity, prolonged expression profile and ability to transduce multiple cell types, has become the leading gene therapy vector. Target diseases have moved beyond currently untreatable inherited dystrophies to common, partially treatable acquired conditions such as exudative age‐related macular degeneration and glaucoma, but use of the technology in these conditions imposes added obligations for caution in vector design. This review discusses the current status of AAV gene therapy trials in genetic and acquired ocular diseases, and explores new scientific developments, which could help ensure effective and safe use of the therapy in the future.
- 21 March 2018
- Published by Springer Nature in Gene Therapy
- Vol. 25 (2) , 115-128
Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a major health problem as evidenced by its increasing incidence and high morbidity and mortality rates. Most patients with HCC have underlying liver disease and dysfunction which limits the current therapeutic options. Treatments that spare the liver and destroy the HCC are needed. Targeting transcriptional differences between HCC and liver cells may provide this therapeutic window. In this study, we examine the potential of the Glypican 3 (GPC3) promoter as a targeting strategy. GPC3 is an oncofetal protein belonging to the proteoglycan family which is normally only expressed during fetal development. However, in HCC, the expression of this protein is reactivated. Here, we show that GPC3 is expressed primarily in HCC and not in normal liver lines. We show that the GPC3 promoter can be used to drive expression of significantly more luciferase and eYFP in HCC cell lines compared to normal liver cells. Further, we show that vectors containing cytosine deaminase (CD) under GPC3 promotor control induced significantly more killing of HCC cell lines after treatment with 5-FC compared to normal liver cell lines. These data suggest that transcriptionally targeted delivery of transgene in HCC cells can be achieved using the GPC3 promoter and this targeting strategy produces limited toxicity to normal liver cells.
- 21 March 2018
- Published by Springer Nature in Gene Therapy
- Vol. 25 (2) , 115-128
Evaluation of the Glypican 3 promoter for transcriptional targeting of hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is a major health problem as evidenced by its increasing incidence and high morbidity and mortality rates. Most patients with HCC have underlying liver disease and dysfunction which limits the current therapeutic options. Treatments that spare the liver and destroy the HCC are needed. Targeting transcriptional differences between HCC and liver cells may provide this therapeutic window. In this study, we examine the potential of the Glypican 3 (GPC3) promoter as a targeting strategy. GPC3 is an oncofetal protein belonging to the proteoglycan family which is normally only expressed during fetal development. However, in HCC, the expression of this protein is reactivated. Here, we show that GPC3 is expressed primarily in HCC and not in normal liver lines. We show that the GPC3 promoter can be used to drive expression of significantly more luciferase and eYFP in HCC cell lines compared to normal liver cells. Further, we show that vectors containing cytosine deaminase (CD) under GPC3 promotor control induced significantly more killing of HCC cell lines after treatment with 5-FC compared to normal liver cell lines. These data suggest that transcriptionally targeted delivery of transgene in HCC cells can be achieved using the GPC3 promoter and this targeting strategy produces limited toxicity to normal liver cells.
- 7 September 2017
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (S259)
The 8‐fold quadrant dissection method for ex vivo human interventional retinal experimentation
Purpose: Retinal research relies on animal and in‐vitro models which lack many of the characteristics of human retina. We have instead established a reproducible ex‐vivo model of primary retinal explants derived from human donor eye cups.Methods: A dissection strategy performed independently by two investigators was designed to maximize retinal tissue whilst maintaining experimentally reproducible fragments of retina suitable for experimental purposes. The retina was divided into 4 quadrants through the fovea and equivalent distribution of photoreceptors between quadrants was confirmed with CD73 staining in 7 pairs of donor eyes with flow cytometry. In the 8 quadrants from each of the 7 donors, the standard error in proportion of photoreceptors was 0.8–2.3%.Results: Cellular composition of free floating retinal explants were followed for 2 months in 10 retinas with quadrant dissection and 8 with random dissection. Explants could be maintained for 2 months with live populations of photoreceptors, ganglion cells and Müller cells detected by flow cytometry. In contrast, amacrine and horizontal cells, decreased by 90% at 7 days. Only quadrant dissection from the same patient showed reproducible and reliable proportions of cell populations between dissections at any time point. There was no statistically significant relationship between the proportion of any cell population and donor age, time after death, time to storage or time in storage.Conclusions: The 8 fold quadrant dissection method from a single donor forms an attractive human experimental model for interventional testing in retinal research. We demonstrate the utility of this model in a simple neuroprotection study, showing that insulin protected against CoCl2 induced hypoxia in human photoreceptors.
- 7 September 2017
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (S259)
The 8‐fold quadrant dissection method for ex vivo human interventional retinal experimentation
Purpose: Retinal research relies on animal and in‐vitro models which lack many of the characteristics of human retina. We have instead established a reproducible ex‐vivo model of primary retinal explants derived from human donor eye cups.Methods: A dissection strategy performed independently by two investigators was designed to maximize retinal tissue whilst maintaining experimentally reproducible fragments of retina suitable for experimental purposes. The retina was divided into 4 quadrants through the fovea and equivalent distribution of photoreceptors between quadrants was confirmed with CD73 staining in 7 pairs of donor eyes with flow cytometry. In the 8 quadrants from each of the 7 donors, the standard error in proportion of photoreceptors was 0.8–2.3%.Results: Cellular composition of free floating retinal explants were followed for 2 months in 10 retinas with quadrant dissection and 8 with random dissection. Explants could be maintained for 2 months with live populations of photoreceptors, ganglion cells and Müller cells detected by flow cytometry. In contrast, amacrine and horizontal cells, decreased by 90% at 7 days. Only quadrant dissection from the same patient showed reproducible and reliable proportions of cell populations between dissections at any time point. There was no statistically significant relationship between the proportion of any cell population and donor age, time after death, time to storage or time in storage.Conclusions: The 8 fold quadrant dissection method from a single donor forms an attractive human experimental model for interventional testing in retinal research. We demonstrate the utility of this model in a simple neuroprotection study, showing that insulin protected against CoCl2 induced hypoxia in human photoreceptors.
- 7 September 2017
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (S259)
Gene therapy targeting of choroidal disease and AAV transcytosis through the outer blood retina barrier epithelium
Purpose: The retinal pigment epithelium (RPE) forms the relatively impermeable outer blood‐retinal barrier, which, when intact, prevents intraocular gene therapy vectors from effectively targeting choroidal diseases such as choroidal melanoma or choroiditis. This study hypotheses that AAV vector optimisation may effectively penetrate this ocular barrier.Methods: Monolayers of aRPE‐19 and primary human RPE were established on 24 well plate transwell inserts and integrity confirmed with stable transepithelial resistance (TEER) of 35±5 Ω/cm2 and resistance to passage of FITC‐Dextran (400 kDa) at 4 weeks. 10^8±1 vgs of AAV serotypes 1, 2, 3, 4, 5, 6, and 8 were added to the apical surface and media collected from the basal surface at various time points. Viral concentrations were measured by qPCR.Results: AAV serotype 6 moved through the intact monolayer of both aRPE‐19 and primary human RPE. 41.5%. 47.4% and 60.4% of AAV‐6 viral particles moved through the monolayer at 30 minutes, 3 hours and 5 hours respectively. Blocking RPE exocytosis with tannic acid prevented movement of AAV6 through the monolayer. All other serotypes were unable to penetrate the RPE monolayer, with less than 10% penetrance at 24 hours.Conclusions: These results indicate that AAV6 passes through a model of the outer blood retina barrier by active intracellular transport. Additionally, this is the first report of AAV‐6 transcytosis across any barrier epithelium. AAV6 may be a promising tool to deliver therapeutic genes for ocular diseases which lay beneath the retinal epithelium.
- 7 September 2017
- Published by Wiley in Acta Ophthalmologica
- Vol. 95 (S259)
Gene therapy targeting of choroidal disease and AAV transcytosis through the outer blood retina barrier epithelium
Purpose: The retinal pigment epithelium (RPE) forms the relatively impermeable outer blood‐retinal barrier, which, when intact, prevents intraocular gene therapy vectors from effectively targeting choroidal diseases such as choroidal melanoma or choroiditis. This study hypotheses that AAV vector optimisation may effectively penetrate this ocular barrier.Methods: Monolayers of aRPE‐19 and primary human RPE were established on 24 well plate transwell inserts and integrity confirmed with stable transepithelial resistance (TEER) of 35±5 Ω/cm2 and resistance to passage of FITC‐Dextran (400 kDa) at 4 weeks. 10^8±1 vgs of AAV serotypes 1, 2, 3, 4, 5, 6, and 8 were added to the apical surface and media collected from the basal surface at various time points. Viral concentrations were measured by qPCR.Results: AAV serotype 6 moved through the intact monolayer of both aRPE‐19 and primary human RPE. 41.5%. 47.4% and 60.4% of AAV‐6 viral particles moved through the monolayer at 30 minutes, 3 hours and 5 hours respectively. Blocking RPE exocytosis with tannic acid prevented movement of AAV6 through the monolayer. All other serotypes were unable to penetrate the RPE monolayer, with less than 10% penetrance at 24 hours.Conclusions: These results indicate that AAV6 passes through a model of the outer blood retina barrier by active intracellular transport. Additionally, this is the first report of AAV‐6 transcytosis across any barrier epithelium. AAV6 may be a promising tool to deliver therapeutic genes for ocular diseases which lay beneath the retinal epithelium.